
Epaxal is used to vaccinate against hepatitis A (infectious jaundice) for adults and children from 1 year of age. The immune system is activated by means of killed hepatitis A virus, bound to virosomes (vaccine particles) consisting of fats (lipids) and proteins. Protection against hepatitis A nfection is achieved in 80-97% of vaccinated individuals after 14 days, in 92-100% after 28 days and in 78-100% after 1 year. Before vaccination with Epaxal, please tell your doctor if you have any problems with your immune system, as this may affect the way the vaccine works.